R01DA054869

7/7 Psychiatric Genomics Consortium: Advancing Discovery and Impact - Project Summary

Now in its 13th year, the Psychiatric Genomics Consortium (PGC) is perhaps the most innovative and productive experiment in the history of psychiatry. The PGC unified the field and attracted a cadre of outstanding scientists (802 investigators from 157 institutions in 41 countries). PGC work has led to the identification of approximately 500 genetic loci in the 11 psychiatric disorders we study. Our work has resulted in 320 papers, many of which have been published in high-profile journals (Nature 3, Cell 5, Science 2, Nat Genet 27, Nat Neurosci 9, Mol Psych 37, Biol Psych 25). As summary statistics are freely available, psychiatric disorders often feature prominently in papers by non-PGC investigators.

To advance discovery and impact, we propose to continue the work of the PGC across 11 disorder groups. Considerable new data are expected to come in the next five years. Therefore, we can rapidly and efficiently increase our knowledge of the fundamental basis of major psychiatric disorders.

Aim 1: We will continue to advance genetic discovery for severe psychiatric disorders in all working groups. We will systematically interface with large biobank studies to ensure maximal comparability and aggressively promote new studies of individuals with psychiatric disorders from diverse ancestries to increase discovery and improve fine-mapping.

Aim 2: Most studies analyze common variation (Aim 1), rare CNV (Aim 2), and rare exome/genome resequencing results (via collaboration) in isolation. We will apply an integrative framework to rigorously evaluate the contributions of all measured types of genetic variation on risk for psychiatric disorders.

Aim 3: We will move beyond classical case-control definitions to a more biologically-based and nuanced understanding. This will be achieved by enabling large trans-diagnostic studies, convening trans-disciplinary teams to use genetics to address unresolved questions about the nature of psychiatric disorders, and promoting large studies of the severest cases seen in psychiatric practice (leveraging the global reach of PGC investigators).

Aim 4: We will work to maximize the impact of our work via translational efforts. This includes close collaborations with neuroscience consortia to understand the biological implications of our findings, identifying modifiable causal risk factors, and robustly predicting clinical outcomes and identifying patient subsets.

Aim 5: We will increase the impact of our work by extending and formalizing outreach to different communities, including pharma and biotech. This will be achieved through digital media platforms such as Twitter, Facebook, and Wikipedia. Additionally, we will develop, distribute, and update resources and educational materials for patients, families, and medical professionals. We will convene a scientific advisory board to ensure we respond positively to those invested in our results.

Successful completion of this body of work will greatly advance knowledge of the genetic basis of psychiatric disorders with potentially major nosological and treatment implications. These goals are consistent with a core mission of the National Institute of Mental Health (NIMH) and the central idea of the PGC: to convert the family history risk factor into biologically, clinically, and therapeutically meaningful insights.

Washington University

TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.242 - Mental Health Research Grants

National Institute on Drug Abuse (NIDA) [HHS - NIH]

National Institute of Mental Health (NIMH) [HHS - NIH]

Missouri United States

State-Wide

Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional) (PAR-19-297)

Amendment Since initial award the total obligations have increased 8434% from $38,822 to $3,313,224.